Topical imiquimod in the treatment of metastatic melanoma to skin

Arch Dermatol. 2003 Mar;139(3):273-6. doi: 10.1001/archderm.139.3.273.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use*
  • Administration, Cutaneous
  • Aged
  • Aged, 80 and over
  • Aminoquinolines / administration & dosage
  • Aminoquinolines / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage
  • Female
  • Humans
  • Imiquimod
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Knee
  • Leg
  • Lymphatic Metastasis
  • Male
  • Melanoma / drug therapy*
  • Melanoma / radiotherapy
  • Melanoma / secondary
  • Melanoma / surgery
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / radiotherapy
  • Neoplasm Recurrence, Local / surgery
  • Nitrosourea Compounds / administration & dosage
  • Organophosphorus Compounds / administration & dosage
  • Recombinant Proteins
  • Scalp
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / radiotherapy
  • Skin Neoplasms / surgery
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Aminoquinolines
  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Nitrosourea Compounds
  • Organophosphorus Compounds
  • Recombinant Proteins
  • Dacarbazine
  • Carboplatin
  • fotemustine
  • Imiquimod